HRP20040732A2 - Synthetic peptides and uses thereof for the preven - Google Patents
Synthetic peptides and uses thereof for the preven Download PDFInfo
- Publication number
- HRP20040732A2 HRP20040732A2 HR20040732A HRP20040732A HRP20040732A2 HR P20040732 A2 HRP20040732 A2 HR P20040732A2 HR 20040732 A HR20040732 A HR 20040732A HR P20040732 A HRP20040732 A HR P20040732A HR P20040732 A2 HRP20040732 A2 HR P20040732A2
- Authority
- HR
- Croatia
- Prior art keywords
- synthetic
- oligopeptides
- oligopeptide
- mmp
- accordance
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 33
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 20
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 title 1
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 134
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 134
- 206010027476 Metastases Diseases 0.000 claims abstract description 39
- 230000009401 metastasis Effects 0.000 claims abstract description 39
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 23
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 23
- 230000009400 cancer invasion Effects 0.000 claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 53
- 201000011510 cancer Diseases 0.000 claims description 52
- 210000004027 cell Anatomy 0.000 claims description 49
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 32
- 230000009545 invasion Effects 0.000 claims description 31
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 125000000539 amino acid group Chemical group 0.000 claims description 19
- 230000004048 modification Effects 0.000 claims description 17
- 238000012986 modification Methods 0.000 claims description 17
- 229960005486 vaccine Drugs 0.000 claims description 14
- 230000000903 blocking effect Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 230000008986 metabolic interaction Effects 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 230000002503 metabolic effect Effects 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000001243 protein synthesis Methods 0.000 claims description 3
- 230000014616 translation Effects 0.000 claims description 3
- 101000573945 Coccidioides posadasii (strain C735) Neutral protease 2 homolog MEP2 Proteins 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract description 20
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract description 20
- 210000002744 extracellular matrix Anatomy 0.000 abstract description 20
- 230000002401 inhibitory effect Effects 0.000 abstract description 15
- 230000001225 therapeutic effect Effects 0.000 abstract description 15
- 150000001413 amino acids Chemical class 0.000 abstract description 13
- 230000015556 catabolic process Effects 0.000 abstract description 4
- 238000006731 degradation reaction Methods 0.000 abstract description 4
- 230000001575 pathological effect Effects 0.000 abstract description 4
- 239000012634 fragment Substances 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 description 15
- 108010082117 matrigel Proteins 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 12
- 201000001441 melanoma Diseases 0.000 description 10
- 230000004709 cell invasion Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000003449 preventive effect Effects 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- -1 t-butoxycarbonyl Chemical group 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- GHLZUHZBBNDWHW-UHFFFAOYSA-N nonanamide Chemical compound CCCCCCCCC(N)=O GHLZUHZBBNDWHW-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002862 amidating effect Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000053150 human MMP2 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35131702P | 2002-01-23 | 2002-01-23 | |
| PCT/EP2003/000659 WO2003062413A1 (en) | 2002-01-23 | 2003-01-23 | Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20040732A2 true HRP20040732A2 (en) | 2005-06-30 |
Family
ID=27613485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20040732A HRP20040732A2 (en) | 2002-01-23 | 2004-08-13 | Synthetic peptides and uses thereof for the preven |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8012935B2 (es) |
| EP (1) | EP1468085B1 (es) |
| JP (1) | JP2005515262A (es) |
| KR (1) | KR20040077764A (es) |
| CN (2) | CN1622992A (es) |
| AT (1) | ATE425247T1 (es) |
| BR (1) | BR0302819A (es) |
| CA (1) | CA2472775A1 (es) |
| DE (1) | DE60326539D1 (es) |
| EE (1) | EE200400030A (es) |
| ES (1) | ES2324027T3 (es) |
| HR (1) | HRP20040732A2 (es) |
| IL (1) | IL162714A0 (es) |
| LV (2) | LV13289B (es) |
| MX (1) | MXPA04007170A (es) |
| NO (1) | NO20034146L (es) |
| NZ (1) | NZ533738A (es) |
| PL (1) | PL209827B1 (es) |
| RU (1) | RU2346043C2 (es) |
| WO (1) | WO2003062413A1 (es) |
| YU (1) | YU76403A (es) |
| ZA (1) | ZA200405328B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2856598B1 (fr) * | 2003-06-25 | 2005-10-28 | Inst Nat Sante Rech Med | Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale |
| JP4911950B2 (ja) * | 2005-11-07 | 2012-04-04 | 晃 伊東 | Ｍｍｐ−１の部分ペプチドを用いた癌浸潤・転移阻害薬 |
| EP2403508B1 (en) * | 2009-03-06 | 2015-10-28 | Université Paris Descartes | Method of treating cancer employing gingival fibroblast conditioned medium |
| US8593732B1 (en) * | 2010-01-23 | 2013-11-26 | Lightsmyth Technologies, Inc. | Partially metallized total internal reflection immersion grating |
| US8003110B1 (en) * | 2011-01-24 | 2011-08-23 | Matthias W. Rath | Metalloproteinase oligopeptides and their therapeutic use |
| EP2649985A1 (en) * | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (III) |
| US20140017267A1 (en) * | 2012-07-13 | 2014-01-16 | Matthias W Rath | Metalloproteinase oligopeptides and their therapeutic use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5280106A (en) | 1988-05-20 | 1994-01-18 | Liotta Lance A | Matrix metalloproteinase peptides: role in diagnosis and therapy |
| GB8817075D0 (en) * | 1988-07-18 | 1988-08-24 | Raychem Ltd | Oscillation suppressor |
| US5646027A (en) * | 1994-09-08 | 1997-07-08 | Warner-Lambert Company | Process for the production of gelatinase catalytic domain protein |
| ES2559317T3 (es) | 1999-10-29 | 2016-02-11 | Glaxosmithkline Biologicals Sa | Péptidos antigénicos de Neisseria |
-
2003
- 2003-01-23 US US10/350,258 patent/US8012935B2/en not_active Expired - Fee Related
- 2003-01-23 PL PL371254A patent/PL209827B1/pl not_active IP Right Cessation
- 2003-01-23 MX MXPA04007170A patent/MXPA04007170A/es not_active Application Discontinuation
- 2003-01-23 DE DE60326539T patent/DE60326539D1/de not_active Expired - Lifetime
- 2003-01-23 KR KR10-2004-7011323A patent/KR20040077764A/ko not_active Application Discontinuation
- 2003-01-23 EE EEP200400030A patent/EE200400030A/xx unknown
- 2003-01-23 CN CNA038026899A patent/CN1622992A/zh active Pending
- 2003-01-23 NZ NZ533738A patent/NZ533738A/xx unknown
- 2003-01-23 YU YU76403A patent/YU76403A/sh unknown
- 2003-01-23 CA CA002472775A patent/CA2472775A1/en not_active Abandoned
- 2003-01-23 JP JP2003562281A patent/JP2005515262A/ja active Pending
- 2003-01-23 BR BR0302819-4A patent/BR0302819A/pt not_active IP Right Cessation
- 2003-01-23 RU RU2004125599/13A patent/RU2346043C2/ru not_active IP Right Cessation
- 2003-01-23 CN CNA2007100054389A patent/CN101007844A/zh active Pending
- 2003-01-23 EP EP03702506A patent/EP1468085B1/en not_active Expired - Lifetime
- 2003-01-23 WO PCT/EP2003/000659 patent/WO2003062413A1/en active IP Right Grant
- 2003-01-23 IL IL16271403A patent/IL162714A0/xx unknown
- 2003-01-23 AT AT03702506T patent/ATE425247T1/de active
- 2003-01-23 ES ES03702506T patent/ES2324027T3/es not_active Expired - Lifetime
- 2003-09-17 NO NO20034146A patent/NO20034146L/no not_active Application Discontinuation
-
2004
- 2004-07-05 ZA ZA200405328A patent/ZA200405328B/en unknown
- 2004-08-13 HR HR20040732A patent/HRP20040732A2/hr not_active Application Discontinuation
- 2004-09-17 LV LVP-04-102A patent/LV13289B/en unknown
-
2005
- 2005-10-17 LV LVP-05-134A patent/LV13419B/lv unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1468085B1 (en) | 2009-03-11 |
| NO20034146L (no) | 2003-10-28 |
| PL209827B1 (pl) | 2011-10-31 |
| ES2324027T3 (es) | 2009-07-29 |
| ZA200405328B (en) | 2006-03-29 |
| RU2004125599A (ru) | 2005-07-10 |
| NZ533738A (en) | 2006-03-31 |
| JP2005515262A (ja) | 2005-05-26 |
| LV13289B (en) | 2005-11-20 |
| US20030139345A1 (en) | 2003-07-24 |
| PL371254A1 (en) | 2005-06-13 |
| MXPA04007170A (es) | 2004-10-29 |
| CN1622992A (zh) | 2005-06-01 |
| US8012935B2 (en) | 2011-09-06 |
| CA2472775A1 (en) | 2003-07-31 |
| ATE425247T1 (de) | 2009-03-15 |
| RU2346043C2 (ru) | 2009-02-10 |
| LV13419B (en) | 2006-09-20 |
| DE60326539D1 (de) | 2009-04-23 |
| KR20040077764A (ko) | 2004-09-06 |
| WO2003062413A1 (en) | 2003-07-31 |
| YU76403A (sh) | 2006-05-25 |
| CN101007844A (zh) | 2007-08-01 |
| EP1468085A1 (en) | 2004-10-20 |
| IL162714A0 (en) | 2005-11-20 |
| EE200400030A (et) | 2004-04-15 |
| NO20034146D0 (no) | 2003-09-17 |
| BR0302819A (pt) | 2004-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006266609C1 (en) | Treatment of tumors | |
| JP2023078424A (ja) | ペプチド組成物の安定性および送達効率を上昇させるための修飾方法 | |
| JP4592772B2 (ja) | δＰＫＣの活性化および阻害のためのペプチド | |
| TW409129B (en) | Factor Xa inhibitors | |
| JPH06504061A (ja) | 神経変性の治療および予防におけるカルパイン阻害剤の使用 | |
| JP2005523326A (ja) | プロテインキナーゼｃのペプチドインヒビター | |
| HUT61322A (en) | Process for producing peptide derivatives suitable for treating glaucoma and pharmaceutical compositions comprising same as active ingredient | |
| LV13419B (en) | Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis | |
| JP2949129B2 (ja) | 胃腸運動刺激活性を有するモチリン類似ポリペプチド | |
| JPH06510987A (ja) | キニノーゲン重鎖のカルパイン抑制性ペプチド同族体 | |
| US20230158100A1 (en) | Treatment of panx1 associates diseases | |
| AU2003205658A1 (en) | Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis | |
| LT5328B (lt) | Sintetiniai peptidai ir jų panaudojimas vėžio invazijos ir metastazių gydymui ir profilaktikai | |
| JP3828214B2 (ja) | ペプチドおよびその塩 | |
| CA2852594A1 (en) | Peptide compounds derived from melanotransferrin and uses thereof | |
| AU2022392824A1 (en) | Peptides and uses thereof | |
| WO2011023213A1 (en) | Modified chemodenervating agents | |
| CN101506225A (zh) | 心脏保护化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20061219 Year of fee payment: 5 |
|
| OBST | Application withdrawn |